We have discovered that a small cationic molecule, GW4869, is cytotoxic to a subset of myeloma cell lines and primary myeloma plasma cells. Biochemical analysis revealed that GW4869 binds to anionic phospholipids such as phosphatidylserine -a lipid normally confined to the intracellular side of the cell membrane. However, interestingly, phosphatidylserine was expressed on the surface of all myeloma cell lines tested (n = 12) and 9/15 primary myeloma samples. Notably, the level of phosphatidylserine expression correlated well with sensitivity to GW4869. Inhibition of cell surface phosphatidylserine exposure with brefeldin A resulted in resistance to GW4869. Finally, GW4869 was shown to delay the growth of phosphatidylserine-high myeloma cells in vivo. To the best of our knowledge, this is the first example of using a small molecule to target phosphatidylserine on malignant cells. This study may provide the rationale for the development of phosphatidylserine-targeting small molecules for the treatment of surface phosphatidylserine-expressing cancers.
Multiple myeloma (MM) is a malignancy characterised by the infiltration of clonotypic plasma cells in the bone marrow. Despite recent advances in treatment, MM remains incurable, and there is still an unmet need for novel therapeutic compounds. When identifying potential therapeutic targets in cancer, the majority of research has focused on proteins, such as signalling enzymes and integral membrane proteins. However, there is a growing appreciation that lipids may also represent attractive targets for cancer therapies. For example, glycolipids, such as various types of gangliosides, and Lewis antigens have been tested as targets in a clinical setting (Dingjan et al, 2015; Soliman et al, 2017) , and the phosphocholine analogues edelfosine and perifosine, which are specific for lipid rafts and lead to alterations in cell surface receptor signalling, have also been assessed in clinical trials (Mollinedo & Gajate, 2015; Nitulescu et al, 2016) . Furthermore, phosphatidylserine (PS), a lipid normally confined to the cytoplasmic side of cell membranes, has emerged as a potential therapeutic target. For example, the novel anti-PS targeting therapeutic monoclonal antibody (mAb), bavituximab, has been evaluated in a number of clinical trials for solid tumours (DeRose et al, 2011; Digumarti et al, 2014) . This is based on the finding that endothelial cells lining tumour blood vessels express cell surface (exoplasmic) PS. Thus, targeting the tumour vasculature with an anti-PS mAb is a potential mechanism to inhibit the growth of malignant cells (DeRose et al, 2011) . In addition, it has been reported that some types of cancer cells, including glioblastoma, melanoma and various types of carcinomas, as well as blood cancer cell lines of myeloid and T cell leukaemia origin, express PS on their surface (Bankovic et al, 2013; Riedl et al, 2011; Schroder-Borm et al, 2005; Utsugi et al, 1991) . Moreover, in some of these studies, cationic peptides have been proposed as potential therapeutics for their ability to preferentially bind to and lyse cell membranes enriched in anionic phospholipids such as PS (Bankovic et al, 2013; Schroder-Borm et al, 2005) .
While screening for anti-MM compounds, we discovered that the small molecule, GW4869, was cytotoxic to a subset of MM cell lines and primary samples and inhibited the growth of RPMI-8226 cells in a xenograft model of MM. GW4869 is highly cationic and hydrophobic, and upon further analysis, we determined that GW4869 binds to membranes enriched in negatively charged lipids. This lead to the discovery that all MM cell lines and MM cells from approximately 60% of patients, express some level of cell surface PS. Interestingly, GW4869 has been described as an inhibitor of neutral sphingomyelinase 2 [nSMase2, also termed sphingomyelin phosphodiesterase 3 (SMPD3)] (Clarke & Hannun, 2006; Marchesini et al, 2003) , however we did not find evidence that GW4869 mediates MM cell cytotoxicity through this pathway. Instead, we found that the specific binding of GW4869 to PS led to gross cell membrane deformities, such as membrane ruffling, clustering of integral membrane proteins and reduced membrane fluidity, which may have contributed to the cytotoxic effects of the compound.
This study is the first to show that a large proportion of MM cells and cell lines express exoplasmic PS. Moreover, we also show, for the first time, that targeting PS with a small cationic molecule can lead to selective cell death of malignant cells. Therefore, our study provides the rationale for the development of anti-PS small molecules as novel therapies for surface PS-expressing cancers.
Methods

Cell lines and primary samples
Daudi, HL-60, K562, Molt-4, NCI-H929 and RPMI-8226 cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). JJN3, Jurkat, LP-1, OPM2 and U266 cell lines were obtained from the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ; Braunschweig, Germany) . No Short Tandem Repeat (STR) analysis was performed on these cell lines as they were obtained directly from the suppliers. ANBL6, Balm and Nalm-6 were obtained from Prof. Leonie Ashman (University of Newcastle, NSW). JIM1, KMS-11 and MM.1S were obtained from Prof. Andrew Spencer (Monash University, Melbourne). WL-2 was obtained from Prof. Douglas Joshua (RPA, Sydney) and KMS-18 was from Prof. Junia Melo (SA Pathology, Adelaide). The identities of KMS-11, MM.1s and Nalm-6 were confirmed by STR analysis performed by the DNA Analysis Facility at Yale University (New Haven, CT, USA). No STR analysis was performed on ANBL6, Balm, JIM1, KMS-18 and WL-2, as at the time of the study, there was no available STR data to match these cell lines against.
All cell lines were routinely tested for mycoplasma contamination. Peripheral blood mononuclear cells (PBMCs) were purified from the buffy coats of normal donors, provided by the Australian Red Cross Blood Service (Alexandria, NSW, Australia), by the Ficoll-Paque purification method. Primary bone marrow samples were collected, with informed consent, from randomly selected patients with newly diagnosed symptomatic MM, seen at the Royal Adelaide Hospital and Mater Adult Hospital, Brisbane. Aspirates of bone marrow were isolated from posterior superior iliac spine and bone marrow mononuclear cells (BMMNCs) were recovered by density gradient centrifugation and used fresh or were cryopreserved for use at another time. Ethical approval for this study was obtained from the Royal Adelaide Hospital and Mater Adult Hospital, Brisbane institutional ethics review committees.
Flow cytometry
Flow cytometry was performed on an LSR II (BD Biosciences, San Jose, CA, USA). GW4869-specific fluorescence was detected using a 405 nm excitation filter and 450/50 nm emission filter (GW4869 spectra shown in Figure S1 ). For PS staining of cell lines, cells were stained with anti-PS mAb (clone 1H6; Merck Millipore, Bayswater, Vic, Australia) or IgG2a isotype control (clone UPC10; Sigma-Aldrich, Castle Hill, NSW, Australia) followed by anti-mouse IgG AlexaFluor 488 or 647 (Thermo Fisher Scientific, Scoresby, Vic, Australia). For primary MM samples, cell surface PS was assessed on CD38 ++ /CD138 + plasma cells by multicolour flow cytometry using anti-PS mAb or IgG2a isotype control followed by anti-mouse IgG2a fluorescein isothiocyanate (FITC; Southern Biotech, Birmingham, AL, USA), CD38-PECy7 (HIT2; BioLegend, San Diego, CA, USA) and CD138-AlexaFluor 647 (B-B4; Bio-Rad, Raleigh, NC, USA) mAbs. Data was assessed using FCS Express (De Novo Software, Glendale, CA, USA).
Cytotoxicity assays
Cells were incubated with serial dilutions of GW4869 or dimethyl sulfoxide (DMSO) under normal tissue culture conditions. At 72 h, cells were harvested and then stained with propidium iodide and assessed for viability by flow cytometry. It should be noted that GW4869 is excited at violet and UV wavelengths (GW4869 spectra shown in Figure S1 ), however this does not interfere with the channel used to detect dead cells which uses a 488 nm laser ( Figure S2 ). were produced in-house using established protocols (Freeman et al, 2011; Sanchez et al, 2013) . Successful engraftment of green fluorescent protein (GFP)-expressing RPMI-8226 cells was confirmed through the detection of human serum lambda light chain with an enzyme-linked immunosorbent assay (ELISA) (Bethyl Laboratories, Montgomery, TX, USA). Two weeks after engraftment, mice were treated with 1Á25 lg/ g GW4869 or 2Á5% DMSO (vehicle) in 200 ll phosphate-buffered saline (PBS) per day. After 14 days of treatment, mice were humanely killed and serum lambda light chain levels determined by ELISA. In addition, the proportion of bone marrow GFP-expressing RPMI-8226 cells in tibiae, femora and lumbar vertebrae was determined by flow cytometry. The sample sizes chosen for the assessment of serum lambda light chain levels as well as the degree of RPMI-8226 bone marrow engraftment were based on previous experiences with this model (Freeman et al, 2011; Sanchez et al, 2013) . The effects of GW4869 on long-term survival was assessed by treating mice daily until mice either succumbed to disease or were humanely killed due to the acquisition of hind limb paralysis or culled at the end (Day 60) of the experiment. The sample size was estimated using a log-rank sample size estimate (Lachin & Foulkes, 1986 ) based on our previous experiences with this model. We assumed that all mice in the control group would be dead with a treated group showing 35% survival with power of 0Á8 and the probability of a type I error of 5%. Moreover, to minimise subjective bias, mice were randomly allocated to the control and treatment group, were kept in the same room in isolated cages, and the studies were performed blinded (an investigator gave the mice a treatment that was not known to them at the time of administration). (Livak & Schmittgen, 2001 ).
Sphingomyelin and ceramide quantification
Lipid extraction was performed according to the method of Matyash et al (2008) . In brief, 2Á5 9 10 5 cells, suspended in methanol, were added to a 2Á0 ml glass vial containing 750 ll methyl tert-butyl ether, 200 ll methanol and 10 ll internal standard mix (ceramide 17:0 and dihydrosphingomyelin 12:0, both at 20 lmol/l concentration). In order to improve detection of sphingomyelin, hydrolysis of fatty acyl esters was induced by addition of a mild base (Le Lay et al, 2009) . Sodium hydroxide was added to a final concentration of 0Á7 mol/l (75 ll of 10 mol/l). Vials were rotated overnight at 4°C. Ammonium acetate (200 ll of 150 mmol/l) was added and the tubes were vortexed for 30 s and centrifuged at 2000 g for 5 min to induce phase separation. The upper organic layer was removed to a new 2 ml glass vial, and stored at À20°C until analysis. Extracts were diluted 5-fold into methanol:chloroform (2:1 v/v) containing 5 mmol/l ammonium acetate prior to mass spectrometric analysis. Mass spectra were acquired using a chip-based nano-electrospray ionization source (TriVersa Nanomate â , Advion, Ithaca, NY, USA) coupled to a hybrid linear ion trap-triple quadrupole mass spectrometer (QTRAP â 5500, SCIEX, Framingham, MA, USA) as described previously (Montgomery et al, 2016) . In brief, 10 ll of extract was aspirated from a sealed 96-well plate (Eppendorf Twin-Tec) and delivered into the mass spectrometer via a nano-electrospray ionization (ESI) chip with an orifice diameter of 4Á1 lm. The delivery gas was N 2 at a pressure of 0Á4 psi and a spray voltage of 1Á2 kV was used for positive ion. The m/z 184Á1 precursor ion scan detected choline containing species (sphingomyelins) and the m/z 264Á4 precursor ion scan detected d18:1 sphingoid-backbone ceramide species. Experimental conditions were a declustering potential of 100 V, entrance potential of 10 V and a scan rate of 200 Da/s. Data were analysed with LipidView â software (SCIEX), including smoothing, identification, removal of isotope contribution from lower mass species and correction for isotope distribution. Quantification was achieved in LipidView â software by comparison of the peak area of individual lipids to their class-specific internal standards after isotope correction.
shRNA lentiviral knockdown of nSMase2
Predesigned pGFP-C-shLenti plasmids encoding 4 unique shRNA targeting human SMPD3 (nSMase2), as well as a scrambled shRNA control, were purchased from OriGene (Rockville, MD, USA; catalogue number TL301492). For expression of lentiviral shRNA constructs in 293T cells, 11 lg of the pGFP-C-shLenti shRNA constructs were cotransfected with 5Á5 lg of VSV-G/pMD2.G and 8Á25 lg pCMV-dR8Á91 using FuGENE6 transfection reagent (Promega, Madison, WI, USA) in a 10 cm plate. The media was then replaced 4 h later, and then the virus-containing media was harvested at 24 and 48 h, and stored at À80°C until use. For lentiviral transduction and stable expression of shRNAs, 1 9 10 6 RPMI-8226 cells were transferred to 6-well plates precoated with recombinant human retronectin fragment (TaKaRa, Mountain View, CA, USA) in 250 ll fresh media containing polybrene (final concentration of 8 lg/ml after addition of lentiviral medium). Lentiviral medium (1 ml) was added to the cells, and the plate was centrifuged at 800 g for 30 min and then transferred to an incubator. After 2 h, 2 ml of fresh media was added, and the cells were then subcultured as required over the subsequent days. At day 4, cells were assessed for transduction efficiency by flow cytometry analysing for GFP expression. Cells were then sorted by flow cytometry into a pure GFP + population with stable expression of the shRNAs. Taqman probes against SMPD3 (Hs00920354_m1) and GAPDH (402869; Thermo Fisher Scientific) were used to assess gene knockdown by qPCR. The pGFP-C-shLenti construct TL301492C showed the lowest expression of SMPD3/ nSMase2 relative to the scrambled control, which was subsequently used in all knockdown experiments.
Survival/growth competition assay
The competition assay was an adaption of a previously described protocol (Jiang et al, 2009 
Fluorescence microscopy
The staining reagents used in this study were anti-CD138 FITC (clone MI15) and anti-CD120b biotin (clone hTNFR-M1) from BD Biosciences, anti-mouse IgG AlexaFluor 488 (catologue number A-11001) and streptavidin AlexaFluor 488 (catologue number S-11223), from Thermo Fisher Scientific.
In some experiments, cells were pretreated with 5 lmol/l GW4869 for 8 h before staining. For surface staining, cells were stained on ice, washed with 1% bovine serum albumin (BSA) PBS, coated onto poly-L-lysine slides and then fixed in 4% paraformaldehyde before analysis by confocal microscopy. For intracellular staining, cells were coated onto poly-L-lysine slides, fixed and then permeabilised with 100 lmol/l digitonin for 10 min. Cells were then washed with PBS 1% BSA 0Á1% Tween and stained with primary and secondary antibodies. Images were acquired on a Nikon A1 confocal microscope and analysed using NIS-Elements (Nikon, Tokyo, Japan).
Fluorescence recovery after photobleaching (FRAP) experiments
OPM2 and RPMI-8226 cells were stained with the cell membrane dye DiI (Thermo Fisher Scientific) and then treated with GW4869 or DMSO control for 4 h under normal tissue culture conditions. Cells were then loaded onto poly-L-lysine coated slides and allowed to rest for 10 min at 37°C. The samples were then analysed on a Nikon A1 confocal microscope using a 100X objective. FRAP experiments were established in three phases using time-lapse data acquisition (500 ms per frame). Phase 1 was the pre-bleach acquisition at an arbitrary laser intensity of 3 (laser 561 nm). Images were recorded over 3 s. Phase 2 was the bleaching acquisition with laser intensity raised to 100 for 8 s. Phase 3 was the post-bleach acquisition at a laser intensity of 3. Post-bleach images were taken over a period of 40 s to allow for fluorescence recovery of the cell membrane. The time-lapses images were then analysed by NIS-Elements software (Nikon). Three regions of interest (ROIs) were used to generate arbitrary fluorescence units over time. ROI 1 measured fluorescence of the bleached region of the cell membrane, ROI 2 measured background fluorescence and ROI 3 measured an unbleached region of the cell membrane. ROIs were then entered into the program easyFRAP using full scale normalisation with a double exponential fitting equation to calculate t-half life and the mobile fraction for each set of images (Rapsomaniki et al, 2012) .
GW4869 phospholipid binding studies
The phospholipids egg phosphatidic acid (PA), 1,2-dioleoyl-snglycero-3-phosphatidylcholine (PC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylethanolamine (PE), egg phosphatidylglycerol (PG), soy phosphatidylinositol (PI), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylserine (PS) and egg sphingomyelin were purchased from Avanti Polar Lipids (Alabaster, AL, USA), while soy phosphatidylinositol (PI) was purchased from SigmaAldrich. The immobilised binding study was an adaption of previous studies performed in our laboratory (Hutchinson et al, 2013 (Hutchinson et al, , 2010 . Briefly, phospholipids were dissolved in ethanol (EtOH) and coated onto hydrophobic PolySorp 96-well plates and N 2 -dried overnight. Plates were then blocked with 1% BSA PBS for 1 h followed by incubation with 10 lmol/l GW4869 or DMSO vehicle control for 3 h at 37°C. After three washes with 0Á3% BSA PBS, the plates were then read on an Infinite 200 plate reader (Tecan, M€ annedorf, Switzerland) measuring GW4869 fluorescence at excitation and emission wavelengths of 368 nm and 492 nm, respectively. To test binding of GW4869 to liposomes, mixtures of lipids were dissolved in chloroform then rotary evaporated to deposit a thin film of dried lipid on the glass bulb. Lipids were then freeze-dried overnight and resuspended in PBS at a concentration of 2Á5 mg/ml followed by extrusion through 100 nm filters (Hutchinson et al, 2013 (Hutchinson et al, , 2010 . GW4869 was then added to the liposome mixture at a final concentration of 10 lmol/l in an 850 ll volume and incubated for 2 h at 37°C. The samples were washed twice with 12 ml PBS with liposomes pelleted by ultracentrifugation at 120 000 g. The bottom 1 ml (liposome) fraction was then collected and GW4869-specific fluorescence measured at excitation and emission of 368 nm and 492 nm, respectively.
Brefeldin A (BFA) treatment of MM cells MM cells were treated with 2 lg/ml BFA (Sigma-Aldrich) or EtOH vehicle for 4 h. Cells were then harvested and immediately stained for PS or treated with 5 lmol/l GW4869 (or DMSO vehicle) for 12 h to measure uptake of GW4869 by flow cytometry. Samples were also assessed for cell viability by propidium iodide staining, as described above.
Statistical analysis
Statistics were performed using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA), and the tests used are indicated in the corresponding figure legends. On that note, t-tests were used when the data was assumed to be normally distributed, and Mann-Whitney tests were used to assess the levels of GFP + RPMI-8226 cell engraftment and serum light chain because the data did not pass the D'Agostino and Pearson omnibus normality test. The variance was not compared between each group of data analysed. A P value of <0Á05 was used to define statistical significance.
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Results
GW4869 is cytotoxic to MM cells
During a screen for small molecule anti-MM compounds, we discovered that the small molecule GW4869 (Clarke & Hannun, 2006; Marchesini et al, 2003 ; see Figure S3 for chemical structure) was cytotoxic to a panel of MM cell lines but not to non-MM cell lines or PBMCs. All MM cell lines in this panel were sensitive to GW4869, with the exception of U266, which was largely resistant (Fig 1A,B) . For some MM cell lines, such as OPM2, cell death was rapid, as a large proportion of dead cells as well as caspase 3/7 + cells could be detected as early as 8 h after treatment (Fig 1C) . Subsequently, we expanded the number of MM cell lines and non-MM cells used in our cytotoxicity panel to 12 MM cell lines and 8 non-MM cell types, in Values are normalised to the no treatment control sample (data points are mean of n = 3 replicates, error bars are AE SEM) (C) RPMI-8226 and OPM2 cell lines were treated with 5 lmol/l GW4869 or DMSO for 8 and 24 h then assayed for caspase 3/7 activity (column heights are mean of n = 3, error bars are AE SEM).
order to determine if particular genotypes or cell types were more susceptible to GW4869 than others (Table I, Table S1 ).
Six of 12 MM cell lines and 1 of 8 non-MM cell types were found to show some level of sensitivity to GW4869. Classification of MM cell lines based on their translocations and expression of oncogenes did not find any association between genetic abnormalities and GW4869 sensitivity. To confirm that GW4869 was also cytotoxic to primary MM cells, we cultured BMMNCs from MM patients with various concentrations of GW4869 or DMSO vehicle control for 24 h. In 2/3 samples, we observed that GW4869 at 0Á4-2Á0 lmol/l reduced the proportion of CD138 + MM cells within primary cell cultures (representative shown in Fig 2) , suggesting specific cytotoxicity of GW4869 to CD138 + MM cells.
GW4869 delays MM tumour growth in a xenograft model
We next set out to determine whether GW4869 could suppress the growth of a MM cell line in vivo. In these experiments we used an established MM xenograft model that replicates human disease, with growth of MM cells within the bone marrow (Freeman et al, 2011; Sanchez et al, 2013) . Briefly, GFP-expressing RPMI-8226 cells were injected i.v. into c-irradiated, CD122 + -depleted NOD/SCID mice. At day 9, mice that were successfully engrafted (determined by detection of human lambda light chain in serum) were treated daily with i.p. injections of 1Á25 lg/g GW4869 or DMSO vehicle control. After 2 weeks of treatment, mice were Moreaux et al (2011) and Ronchetti et al (2001) . †PS status: geometric mean fluorescence intensity values > 1000 = High, 100-1000 = Moderate, 25-100 = Low, 0-25 = None. rates were assessed. The GW4869-treated group showed reduced levels of lambda light chain (mean: 0Á7 vs. 1Á9 lg/ml for GW4869 and vehicle, respectively; Fig 3A) . There was also a decrease in GFP + RPMI-8226 cells in the GW4869-treated group in the femur/tibia as well as the lumbar spine which was not significant ( Fig 3B) ; however, when both tissues were combined, GW4869-treated mice showed a significant decrease in the levels of GFP + RPMI-8226 cells relative to the vehicle control (Fig 3C) . Finally, we performed a long-term survival experiment where mice were treated daily with GW4869 or vehicle. The GW4869-treated group survived longer than the vehicle control-treated group with the median survival time of 38 and 28 days, respectively (hazard ratio: 2Á61, 95% confidence interval: 1Á13-9Á07; Fig 3D) . These findings confirm that GW4869 is capable of suppressing MM growth in vivo.
nSMase2 expression does not correlate with sensitivity to GW4869
In order to understand the mechanism by which GW4869 is cytotoxic to MM cells, we initially tested the expression of its presumed target, nSMase2 (Clarke & Hannun, 2006; Marchesini et al, 2003; Shamseddine et al, 2015) , in MM cell lines and in GW4869-resistant non-MM cells. nSMase2 and its gene (SMPD3) were detected in all cell lines by Western blot and qPCR, respectively (Fig 4A,B) . However, there was no association between nSMase2 expression and sensitivity to GW4869 as one of the most GW4869-sensitive cell lines, OPM2, had close to undetectable levels of nSMase2. Furthermore, two GW4869-resistant non-MM cell lines, Jurkat and K562, displayed similar levels of nSMase2 to the GW4869-sensitive MM cell lines NCI-H929 and JJN3.
To ascertain whether GW4869 suppresses the turnover of sphingomyelin to ceramide, and thus inhibits nSMase2 in MM cells, we treated RPMI-8226 and OPM2 cells with GW4869 for 4, 9 and 24 h and then measured total sphingomyelin and ceramide species by ESI-MS. In contrast to the expected effects of nSMase2 inhibition, the molar levels of sphingomyelin decreased while ceramide increased in treated cells suggesting that GW4869 is not inhibiting nSMase2 in MM cells (Fig 4C) . We then used a shRNA specific for SMPD3 (the gene that encodes nSMase2) and delivered by a GFP-expressing lentiviral vector, to knockdown the expression of the enzyme in GW4869 sensitive RPMI-8226 cells. We achieved a knockdown of SMPD3/nSMase2 expression of approximately 4-fold at the mRNA level (23Á5% of the scrambled control Fig 5A) , however there was only a modest, but not convincing knockdown of nSMase2 by Western blot (~20% knockdown of nSMase2 compared to control; Fig 5B) . Nevertheless, we then assessed the effects of SMPD3 shRNA knockdown on cellular survival and proliferation by using a competition assay. This assay measures the relative abundance of GFP + shRNA-expressing cells in a partially transduced population over time. GFP + cells that express an shRNA that confers a survival disadvantage and/or inhibits proliferation will be outgrown by the non-transduced GFP À cells (Jiang et al, 2009) . We found that the GFP + transduced cells grew at the same rate as GFP -non-transduced cells for both the scrambled and SMPD3 shRNA samples (Fig 5C) . This suggests that reduced SMPD3 mRNA expression has no effect on RPMI-8226 cell survival/proliferation. Finally, we tested the ability of GW4869 to induce cytotoxicity in RPMI-8226 cells with reduced SMPD3 mRNA expression. We found that there was no difference in the amount of cell death between the scrambled and SMPD3 shRNA-expressing cells. Given that nSMase2 protein levels were not convincingly knocked down by SMPD3 shRNAs, we cannot conclude GW4869 delays multiple myeloma (MM) cell growth in a xenograft model. CD122 + depleted MM-bearing NOD/SCID mice were treated daily with i.p. injections of 1Á25 lg/g GW4869 (n = 8) or dimethyl sulphoxide (DMSO) vehicle control (n = 7). After 2 weeks, mice were culled and assessed for (A) serum lambda light chain levels by enzyme-linked immunosorbent assay or (B) the proportion of GFP + RPMI-8226 cells in the femur/tibia and lumbar spine (**P-value < 0Á01, n.s. not significant, two-tailed Mann-Whitney test). (C) Combined proportion of GFP + RPMI-8226 cells (DMSO normalised, *P-value < 0Á05, two-tailed Mann-Whitney). (D) Kaplan-Meier plots showing survival of MM-bearing mice treated daily with GW4869 (n = 10) or DMSO vehicle control (n = 9) until they succumbed to hind-limb paralysis or death (*P-value < 0Á05, two-tailed log-rank test, error bars are AE SEM).
with confidence that the cytotoxic effects of GW4869 on MM cells is independent of nSMase2 inhibition. However, when combined with the fact that GW4869 does not inhibit the turnover of sphingomyelin to ceramide in these cells, as well as there being no correlation between nSMase2 expression and GW4869 sensitivity, there is no evidence to support that the cytotoxic effects of GW4869 is due to direct nSMase2 inhibition.
GW4869 localizes and deforms the cell membrane of MM cells
GW4869 shows an excitation and emission peak at 368 nm and 492 nm, respectively ( Figure S1 , which makes it suitable to use in fluorescence applications. We used these properties of GW4869 to define its subcellular localisation in MM cells, and found that GW4869 co-localised with the cell membrane markers CD138 and CD120b on RPMI-8226 cells (Fig 6) . Importantly, there was no bleed through of GW4869-specific fluorescence into the green channel ( Figure S4 ). Another observation was that the cell membranes of these GW4869-treated cells were grossly deformed and ruffled, with both CD138 and CD120b clustered alongside GW4869 in the same region of the cell. This was in contrast to vehicle controltreated cells where both CD138 and CD120b were more uniformly distributed around the cell membrane (Fig 6) . These results suggest that GW4869 interacts with a component of the cell membrane and causes distortions in regions where it accumulates.
In order to assess other morphological changes in the cell membrane of GW4869-treated MM cells, we performed FRAP experiments to measure the effects of the compound on cell membrane fluidity, which is a critical aspect of cellular function (Nicolson, 2014) . GW4869-treated OPM2 cells were found to have significantly reduced membrane fluidity relative to vehicle-treated cells, with a mean half-life of 4Á87 s vs. 2Á67 s for DMSO (Table II) . Furthermore, the mobile fraction, a measure of how many molecules are in a fluid state as opposed to solid state in the cell membrane (1Á0 being all molecules fluid and 0Á0 being no molecules fluid), had a mean value of 0Á91 for DMSO-treated cells versus 0Á64 for GW4869-treated cells (Table II, Fig 7) . Similar results were also observed with RPMI-8226 cells (mean t-half-life of 4Á40 s and 7Á10 s, and mean mobile fraction of 0Á85 and 0Á69 for DMSO and GW4869, respectively; Table II ). This data clearly shows that GW4869 rigidifies the cell membrane of MM cells and provides further evidence that this compound induces gross cell membrane deformities.
GW4869 binds to anionic phospholipids
The fact that GW4869 localises to the cell membrane of MM cells as well as being very hydrophobic suggested that the Cells were then harvested and assessed for sphingomyelin and ceramide levels (column heights are mean of n = 3 replicates, error bars are AE SEM, *P-value < 0Á05, ***Pvalue < 0Á001, two-tailed t-test). PBMCs, peripheral blood monoclonal cells.
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molecule might bind directly to the bilayer through associating with cell membrane lipids. To test this hypothesis, we assessed the ability of GW4869 to interact with different classes of phospholipid species immobilised onto 96-well hydrophobic plates. Interestingly, GW4869 showed high levels of binding to the anionic phospholipids PS, PA and PG. In contrast, little to no binding of GW4869 was observed for sphingomyelin, PC, PE and PI (Fig 8A) . To confirm that GW4869 interacts with anionic phospholipids, we synthesised liposomes composed of different ratios of anionic to zwitterionic lipid species. In this assay, the zwitterionic phospholipid PC was used as the base lipid as this forms stable liposomes. PC was used alone or mixed in a 3:1 ratio with the anionic phospholipids PS or PA. Liposomes were then incubated with 10 lmol/l GW4869 for 2 h and washed extensively to remove unbound GW4869. The liposome fraction was then assessed for GW4869 uptake by measuring direct fluorescence of the compound. GW4869 bound strongly to PS/PC and PA/PC liposomes and showed low levels of binding to PC only liposomes, which confirmed that GW4869 preferentially binds to anionic phospholipids (Fig 8B) .
MM cells express surface exposed PS
The fact that GW4869 binds to anionic phospholipids as well as being incorporated into the membrane of MM cells suggests that the cytotoxic effects of the compound may be due to the presence of cell surface anionic phospholipids. In order to investigate this, we initially tested the ability for GW4869 to be taken up into the cell membranes of GW4869-sensitive MM cells and GW4869-resistant non-MM cells. Cells were treated for 4 h with 5 lmol/l GW4869 and then assessed by flow cytometry to assess GW4869-specific fluorescence. Interestingly, the MM cells incorporated high levels of GW4869 into their cell membranes with U266 cells, which are resistant to GW4869, showing the least amount of uptake. In contrast, the non-MM cells showed only low levels of GW4869 uptake (Fig 9A,B,C) . We also assessed the ability of GW4869 to be incorporated into MM cells in vivo. After 10 days of treatment, approximately 25% of bone marrow GFP + RPMI-8226 cells had taken up GW4869, thus confirming that the small cationic molecule can interact with MM cells in vivo ( Fig 9D) . As GW4869 bound strongly to PS, the major anionic phospholipid found in eukaryotic cell membranes (Leventis & Grinstein, 2010) , we stained MM cell lines and non-MM cells with an anti-PS mAb to determine if sensitivity to GW4869 by MM cells could result from the presence of anionic phospholipids on the cell surface. All MM cell lines tested were found to express cell surface PS, with 6/ 12 MM cell lines expressing high levels of cell surface PS (Table I ). In addition, RPMI-8226 cells engrafted into the bone marrow of CD122 + -depleted NOD/SCID mice were also found to express high levels of surface PS (Fig 10A) . In contrast, PBMCs and the majority of non-MM cell lines tested did not express cell surface PS (Fig 10B, Table S1 ).
The sensitivity of cells to GW4869 correlated closely with PS expression. For example, 5 out of the 6 high PS expressing cell lines were sensitive to GW4869, and for the moderate PS expressing cell lines, 2/5 were sensitive (this includes the B-ALL cell line, Nalm-6). In contrast, all cell types with either low or no PS expression were found to be resistant to GW4869 (Table I, Table S1 ). Therefore, these results show that the levels of PS expression correlate well with sensitivity to GW4869. Extracellular exposure of PS is normally synonymous with dead or dying cells, such as in apoptosis. However, MM cell lines were not found to be apoptotic, as they: (i) did not show any increase in basal caspase 3/7 + activity over non-MM cell lines ( Figure S5 ), and (ii) induction of apoptosis using mitomycin C induced a two order of magnitude increase in cell surface PS compared with untreated MM cells (Fig 10C) . Given that extracellular PS was expressed on MM cell lines, we also stained MM CD138 + primary cells to ascertain whether they also expose PS. Nine out of 15 samples showed some level of externalised PS on CD38 + /CD138 + MM plasma cells. Of these PS positive samples, five were found to express moderate to high levels of PS with the other four having detectable but low levels on the surface (Fig 10D,E ; Table S2 ). Two of the three primary patient samples tested for GW4869-specific cytotoxicity (Fig 2, above) were also assessed for cell surface PS expression. Interestingly, the GW4869-resistant patient was a non-PS expressor, whereas the GW4869-sensitive patient tested was found to express Values in square brackets denote standard deviation. P-values calculated using a two-tailed t-test. **denotes P-value <0.01 ****denotes P-value <0.0001 
Secretion is responsible for PS exposure on MM cells
It has been found that excited neuronal cells and activated mast cells can 'flip-out' PS onto the extracellular face, which is thought to be as a result of the fusion of intracellular compartments, such as secretory vesicles, with the cell membrane (Leventis & Grinstein, 2010; Ory et al, 2013) . Given that MM cells are highly secretory due to synthesis of immunoglobulin, we set out to determine whether PS exposure is related to secretion in these cells. MM cell lines were treated with the well-known secretion inhibitor BFA or vehicle control for 4 h and then stained for PS as before. All cell lines were found to down regulate the levels of PS on their surface by approximately 25 to 50% with BFA treatment, suggesting that secretion is at least partly responsible for this phenomenon (Fig 11A) . We then incubated the same cells with GW4869 for 12 h and found that BFA-treated samples accumulated 50-75% lower amounts of GW4869 compared with vehicle control-treated cells (Fig 11A) . In addition to this, we also assessed the ability for BFA to inhibit GW4869-specific cytotoxicity. As BFA is cytotoxic within 24-48 h, we conducted our experiment over a shorter time period (16 h total). RPMI-8226 cells and OPM2 cells were pre-treated with BFA or EtOH vehicle control for 4 h followed by incubation with GW4869 or DMSO vehicle control for 12 h before assessment of cell viability. As expected, cells pre-treated with EtOH vehicle control were susceptible to GW4869 with approximately 25% more cytotoxicity than DMSO for both cell lines. However, there was no difference in viability between DMSO and GW4869 for the BFA pre-treated samples (Fig 11B) . Given that BFA-treated cells became resistant to the effects of GW4869, our results suggest that PS exposure and subsequent cytotoxicity to GW4869 may be attributed to secretion by MM cells.
Discussion
We demonstrate that a large proportion of MM cells and cell lines express exoplasmic PS. Moreover, targeting PS with a small cationic molecule can induce cytotoxicity in high surface PS-expressing MM cells and inhibit the growth of MM cells in vivo. PS is normally confined to the intracellular side of the cell membrane in healthy cells through an active process that is regulated by the activity of ATP-driven flippases.
It is well-known that dead or dying cells lose the ability to regulate cell membrane asymmetry resulting in the exoplasmic expression of PS (Leventis & Grinstein, 2010) . However in our studies, cell surface PS-expressing MM cells were not found to be apoptotic. Cell surface PS has also been described for other cell types, such as activated platelets, mast and PS or PC and PA (3: 1 ratio of PC to anionic lipid; column heights are mean of n = 3 replicates, error bars are AE SEM). PA, phosphatidic acid; PC, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; PE, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylserine.
cells and neuronal cells (Leventis & Grinstein, 2010; Ory et al, 2013) . Additionally, it has also been shown that a number of cancer types, including glioblastoma and melanoma, as well as endothelial cells in tumour vasculature can express exoplasmic PS (DeRose et al, 2011; Riedl et al, 2011) . The mechanisms that induce PS exposure on the surface of these cells are not well understood. One theory posits that activated cells increase cytoplasmic Ca 2+ levels which, in turn, activate scramblases, leading to PS translocation to the cell surface (Riedl et al, 2011) . It has also been proposed that exocytosis of secretory vesicles can lead to the transient exposure of PS as a consequence of local perturbations from membrane fusion, or the presence of PS on the outer leaflet of secretory vesicle membranes (Martin et al, 2000; Zwaal & Schroit, 1997) . In relation to our studies, we present evidence that at least some of the PS exposure on MM cells may be attributed to secretion. Indeed, MM cells are considered a secretory cell given that they synthesise and secrete large amounts of immunoglobulin. Therefore PS exposure may be a general property of cells actively involved in secretion.
The small cationic molecule GW4869 is the most commonly used inhibitor of nSMase2 in cell-based assays (Shamseddine et al, 2015) . In our studies, we did not find evidence that the cytotoxic effects of GW4869 in MM cells could be attributed to inhibition of nSMase2. For example, cells of the OPM2 cell line, which is one of the most sensitive cell lines to GW4869, showed low to undetectable levels of nSMase2 expression. Furthermore, the ratio of sphingomyelin to ceramide remains unchanged or actually decreases in GW4869-treated MM cell lines, which is in contrast to the expected effects of nSMase2 inhibition. Unfortunately, we were unable to definitely rule out nSMase2 in the cytotoxic pathway as specific knockdown with shRNAs only resulted in a modest and unconvincing knockdown at the protein level (despite SMPD3 mRNA levels being~25% of control). Therefore subsequent studies may need to use more effective knockdown strategies, such as the use of Clustered regularly interspaced short palindromic repeats (CRISPR)/ Cas9 to disrupt expression all together and confirm that GW4869-induced cytotoxicity is independent of nSMase2.
Our results suggest sensitivity to GW4869 is dependent upon surface expression of PS. This was based on the observation that GW4869 binds to anionic phospholipids, such as PS, that the levels of surface PS expression are well correlated with sensitivity to GW4869, and that reduction in exoplasmic PS levels using BFA causes a lower uptake of GW4869 and reduced cytotoxicity of the compound. Interestingly, PS is a co-factor for nSMase2 activity (Marchesini et al, 2003; Shamseddine et al, 2015) . Therefore, the GW4869 inhibition of nSMase2 observed in other studies may occur indirectly, through binding and sequestration of PS. Nevertheless, the fact that GW4869 binds to anionic phospholipids suggests that the inhibitor is not as specific to nSMase2 as previously thought. Results using GW4869 should be interpreted with caution unless supported by other inhibitors, such as siRNAs or targeted gene disruption complexes, confirming that phenotypic changes are due to inhibition of nSMase2 and not through interaction with anionic phospholipids. On that note, we have reported phenotypic changes in MM cells treated with GW4869 in a prior study (Hutchinson et al, 2010) . This was assumed to be due to nSMase2 inhibition; however, the end point of these experiments was at 48 h, a time that the many of these cells are dead or dying. Thus it is possible that phenotypic changes were due to cytotoxic effects of the compound targeting cell surface PS rather than through nSMase2 inhibition (Hutchinson et al, 2010) . GW4869 is also frequently used as an inhibitor of exosome secretion, which is attributed to nSMase2 inhibition (Colombo et al, 2014) . However, exosomes display PS on both sides of the membrane (Matsumoto et al, 2017) . Therefore inhibition of exosome secretion by GW4869 may be due to binding to PS on the exosome membrane rather than through nSMase2 inhibition, which should be explored in subsequent studies.
There are a number of possible mechanisms to explain the cytotoxic effects induced by GW4869 binding to PS. GW4869 was found to grossly deform the cell membrane, which led to significant changes in fluidity as well as clustering of integral membrane proteins. The regulation of cell membrane fluidity is an essential aspect of cellular function (Nicolson, 2014) , and the rigidifying effects of GW4869 may have disrupted critical pathways, such as the transportation of nutrients or disruption of cell signalling, which are required for cell survival. On the other hand, the clustering of integral membrane proteins, which was also observed in our study, can lead to aberrant cell signalling and subsequent cell death (Gajate & Mollinedo, 2007; Sessler et al, 2013) . That said, caspase 8 is a known inducer of the extrinsic (cell membrane) apoptotic pathway (Lavrik et al, 2005; Sessler et al, 2013) . However, we found no evidence of caspase 8 activation, nor were we able to block cytotoxicity using a specific inhibitor of caspase 8 ( Figure S6 ). We also assessed caspase 9 activation to see if there is any evidence that the intrinsic apoptosis pathway is activated, however similar to caspase 8, there was no detectable increase in caspase 9 activity ( Figure S7 ). Alternatively, GW4869 may disrupt cell membrane integrity. For example, the compound is large and highly cationic (predicted pK a of 9Á68), which probably mediates its interaction with anionic phospholipids, and in many ways it resembles a cationic peptide, such as a defensin. Cationic peptides are cytolysins that preferentially interact with anionic membranes (Bankovic et al, 2013; Ganz, 2003; Liu et al, 2016; Schroder-Borm et al, 2005) . Thus it is possible that GW4869 acts in a similar manner to these peptides by accumulating on the surface of anionic phospholipids and eventually disrupting cell membrane integrity, leading to cell death.
The levels of PS expression are associated with sensitivity to GW4869. For example, 5/6 high PS expressing cell lines are sensitive to GW4869, whereas only 1/4 moderate PS expressing MM cell lines showed susceptibility to GW4869. Thus small molecules targeting PS are likely to be most effective in this high PS expressing subgroup. In relation to MM patients, our results suggest that high cell surface PS expression is a feature of MM plasma cells from a subset of patients (2/15 samples analysed). Furthermore, it appears that MM primary cells with high PS expression are sensitive at relatively low concentrations of GW4869, however dose responses remain to be defined, and it is also not known if primary MM plasma cells expressing moderate levels of PS might be sensitive to GW4869, which will need to be addressed in subsequent studies. Although high levels of PS expression is characteristic of only a small subgroup of MM patients, this is still significant given the current trend towards personalised, MM subtype-specific therapies. For example, the finding that 4% of MM patients express activating mutations in the oncogene BRAF (Chapman et al, 2011) , led to the clinical testing of BRAF inhibitors in this subgroup of patients (Hyman et al, 2015) .
Another avenue to explore is whether surface PS expression is related to the stage of disease, and whether it could be used as a prognostic marker for MM. Although not the purpose of this study, it is interesting to note there does not appear to be any correlation between surface PS expression and the stage of MM (according to the International Scoring System classification). However, of the moderate to high PS expressing samples where there is information on survival, only 1/4 patients were still alive at follow-up as opposed to 6/8 patients with low to no PS expression. This suggests that the levels of PS expression might be negatively correlated with survival, which could be confirmed using a larger pool of patient samples. replicates, error bars are AE SEM, *P-value < 0Á05, **P-value < 0Á01, two-tailed one sample t-test). (B) RPMI-8226 cells and OPM2 cells were pre-treated BFA or EtOH vehicle control for 4 h, and then treated with 5 lmol/l GW4869 or DMSO for 12 h. Cells were then harvested and cell viability was determined by flow cytometry. Percent viability was normalised to the DMSO control samples (column heights are mean of n = 3 replicates, error bars are AE SEM, *P-value < 0Á05, ns: not significant, two-tailed t-test). BFA, brefeldin A; DMSO, dimethyl sulfoxide; EtOH, ethanol; geoMFI, geometric mean fluorescence intensity; PS, phosphatidylserine.
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GW4869 is only a 'proof of concept' first generation compound and there is probably much room to improve its potency and pharmacokinetics. For example, after a 10-day treatment with GW4869, approximately 25% of RPMI-8226 cells had taken up the compound in vivo. This was modest, however it was enough to delay the growth of these cells in this model. Therefore subsequent medicinal chemistry studies should focus on improving the pharmacokinetics and potency of second generation anti-PS compounds to enhance their efficacy in vivo, as well as testing them for synergistic effects with other types of therapies, especially those that are already approved for the treatment of MM. Finally, PS targeting small molecules should be assessed on other types of cancers given the fact that the B-ALL cell line, Nalm-6, was found to express PS and was also sensitive to GW4869. This includes PS-expressing cancers, such as glioblastoma and melanoma (Riedl et al, 2011; Utsugi et al, 1991) . Moreover, there are only a small number of studies reporting the surface expression of PS on malignant cells (Bankovic et al, 2013; Riedl et al, 2011; Schroder-Borm et al, 2005) , so subsequent studies will be required to determine the PS expression profile on other types of cancers as well as their sensitivity to PS targeting agents.
To the best of our knowledge, this is the first study to demonstrate that a small molecule targeting PS can lead to the selective cytotoxicity of surface PS-expressing malignant cells and inhibiting the growth of MM cells in vivo. Moreover, exoplasmic PS has been considered a potential therapeutic target for a variety of other cancers (Bankovic et al, 2013; Riedl et al, 2011; Schroder-Borm et al, 2005) . It is also found on the surface of vasculature endothelial cells within solid tumours. This has led to the preclinical and clinical testing of novel PS-targeting molecules, such as cationic peptides and anti-PS mAbs (Bankovic et al, 2013; DeRose et al, 2011; Schroder-Borm et al, 2005) ; however, a small molecule approach has yet to be assessed. Given the findings of our study, we argue that novel PS targeting small molecules should also be evaluated as an alternative therapeutic strategy for the treatment of surface PS-expressing tumours.
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